CONKAY MEDICAL SYSTEMS' STORY
Treating the untreated
Affecting more than 100 million people, valvular regurgitation occurs when one of the heart’s valves fails to close tightly, allowing blood to flow backward. Patients experience shortness of breath, fatigue, chest pain, fluttering heartbeat and sometimes death.
Traditional treatments are anything but, as they have severe limitations or require patients to remain on undesirable medications, including blood thinners and diuretics. ConKay Medical Systems has developed a one-size-fits-all annular repair catheter system focused on the tricuspid valve. ConKay’s device replicates effective surgical treatments without the attendant risks of open-heart surgery.
“Unorthodox Ventures has experience working with innovative medical device companies and understands what a difference a device like ours makes to a person’s quality of life. We’re proud to work with them as we continue our development.”
- Albert Yuan, Founder & CEO
ConKay Medical Systems in the Media
BioSpace – ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round
Cardiac Wire – ConKay’s Valvular Seed Round
CardiovascularNews – Funding Round Closes in Support of ConKay Annuloplasty System for TR Treatment
FinSMES – ConKay Medical Systems Raises $1.8M in Seed Funding
G-MedTech News Center – ConKay Medical Systems Closes $1.8M Seed Financing Round
Life Science Intelligence – A Matter of Innovation Studio Interview
MassDevice – MedTech Innovator Names 50 Startups in Cohort for 2022 Accelerator Program
Medical Device Network – ConKay Raises $1.8M to Propel Heart Valve Catheter into Trials
MedTech World – Beating Heart Disease: How ConKay Leads the Charge Against Valvular Regurgitation
Slice of Healthcare – ConKay Medical Secures $1.8M in Oversubscribed Seed Funding
Startup Rise – CA-based ConKay Medical Systems Secures $1.8 Million in Seed Funding
Brand Recognition
American Heart Association – EmPOWERED to Serve Business Accelerator
MedTech Innovator – 2022 Top 50
MedTech Innovator – Bay Area Business Accelerator Finalist
University of California San Francisco – 2023 Rosenman Innovators